iTBS vs Standard rTMS: A Decade of Equivalence Evidence

Patients researching transcranial magnetic stimulation encounter two protocol names — standard 10 Hz rTMS and intermittent theta-burst stimulation (iTBS) — and reasonably ask which one is "better." The clinical answer, established in the THREE-D non-inferiority trial (Blumberger et al., Lancet 2018) and reinforced by a decade of subsequent meta-analyses and real-world data, is that iTBS produces equivalent response and remission rates to standard 10 Hz rTMS in major depressive disorder, with each session running roughly one-third as long.¹ This article walks through what each protocol actually is, the mechanism the two share, the pivotal evidence and the supporting decade of replication, and the clinical implications — throughput, patient burden, tolerability, and coverage — that follow from the equivalence finding.

The two protocols, side by side

Both protocols target the left dorsolateral prefrontal cortex (DLPFC). Standard 10 Hz rTMS is delivered at 120% of the individualized motor threshold, the parameter framework recommended by the Clinical TMS Society consensus.² Stimulation intensity for iTBS is individualized to each patient; in our clinic it is delivered at up to 90% of the motor threshold. The two protocols otherwise differ in the pulse pattern.

Standard 10 Hz rTMS

The original Food and Drug Administration-cleared protocol for major depressive disorder, sometimes called "high-frequency rTMS," delivers pulses at 10 Hz in 4-second trains separated by 26-second inter-train intervals, for approximately 3,000 pulses per session over roughly 37.5 minutes of active stimulation. Including coil positioning and a brief post-session check, total in-chair appointment time runs approximately 40 minutes.²

Intermittent theta-burst stimulation (iTBS)

iTBS is a patterned-burst protocol designed by Huang and colleagues (2005) to mimic the endogenous theta-rhythm bursts that produce robust long-term potentiation in hippocampal slice preparations.³ The pattern: three pulses at 50 Hz form a single burst; bursts repeat at 5 Hz (the theta rhythm); stimulation alternates 2 seconds on and 8 seconds off, for 600 pulses total in approximately 3 minutes and 9 seconds of active stimulation. Including positioning, total in-chair appointment time runs approximately 10–20 minutes.

Both protocols are FDA-cleared under the 510(k) pathway for major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication. The first iTBS-specific clearance for adult MDD was granted in 2018 (NeuroStar Express, K183320); multiple cleared devices now offer both protocols.⁴ iTBS does not require a separate insurance authorization track from 10 Hz rTMS — both are covered under the same TMS payer policies.

The mechanism the two protocols share

Both 10 Hz rTMS and iTBS are thought to produce their antidepressant effect through synaptic plasticity analogous to long-term potentiation (LTP) and long-term depression (LTD) — the cellular mechanisms underlying learning and memory.⁵ A single pulse depolarizes neurons in a focal cortical region; a repetitive train produces effects that outlast the stimulation itself, on the order of minutes to hours after a single session and weeks to months after a complete course.

The theoretical case for iTBS was that the theta-burst pattern more efficiently engages the LTP-like response observed in animal models.³ In Huang's original human motor-cortex study, a 190-second iTBS train produced measurable cortical excitability changes lasting longer than the train itself, demonstrating that a patterned-burst protocol could engage plasticity in a fraction of the time a conventional 10 Hz train required.

A reasonable prediction would have been that iTBS, by exploiting the natural plasticity rhythm, would outperform 10 Hz rTMS clinically. That prediction is not what the clinical evidence has shown. The two protocols engage the same underlying mechanism, and clinical effect sizes are comparable — the time efficiency is the gain, not greater efficacy.

The pivotal trial — Blumberger 2018 (THREE-D)

The equivalence finding rests on a single high-quality randomized non-inferiority trial. THREE-D (Blumberger et al., Lancet 2018) was a multi-site, randomized, blinded non-inferiority trial of 414 adults with treatment-resistant depression randomized to a 4–6 week course of either iTBS (n = 209) or standard 10 Hz rTMS (n = 205) over the left DLPFC at 120% of motor threshold.¹

Headline findings:

• Response rate (≥50% reduction in HAM-D-17): 49% iTBS vs 47% rTMS — non-inferior.
• Remission rate: 32% iTBS vs 27% rTMS — non-inferior.
• Tolerability: comparable. No clinically significant difference in dropout rates or in the incidence of headache, scalp discomfort, or other adverse events.
• Per-session time: iTBS approximately 3 minutes of active stimulation vs approximately 37.5 minutes for 10 Hz rTMS.

THREE-D is the basis on which iTBS entered routine clinical use as an alternative to standard 10 Hz rTMS. It is the trial most TMS clinicians cite when explaining the choice between protocols to patients.

The decade of replication

A single non-inferiority trial, even a well-powered multi-site one, is not by itself a "decade of equivalence." That framing rests on the meta-analyses and real-world studies that have followed.

Berlim 2017 — earlier meta-analytic signal. Before THREE-D was published, Berlim and colleagues conducted a meta-analysis of the smaller theta-burst-versus-rTMS comparisons that had been done in major depression, finding comparable response and remission rates between protocols.⁶ This was the earliest meta-analytic signal that the eventual THREE-D result was likely.

Voineskos 2022 — confirmatory meta-analysis. A subsequent meta-analysis, pooling THREE-D with the additional iTBS-versus-rTMS comparisons published in its wake, confirmed the equivalence finding at the meta-analytic level — pooled response and remission rates did not differ statistically between protocols.⁷

Bulteau 2022 — real-world clinical effectiveness. Outside the trial setting, a real-world cohort study examined iTBS effectiveness in routine clinical practice and found response and remission rates comparable to those reported for 10 Hz rTMS in the major naturalistic registries.⁸ Effectiveness data outside randomized trials is the most relevant evidence for the question patients actually ask — will this work in a community clinic, not just in a research center?

Taken together, the THREE-D trial plus the surrounding meta-analytic and real-world literature is the basis for the now-routine clinical position: iTBS and standard 10 Hz rTMS are equivalent first-line TMS protocols for major depressive disorder, and the choice between them is a clinical-and-logistical judgment rather than an efficacy trade-off.

What the equivalence finding does — and does not — mean

Clinical implications that follow from equivalence

Throughput and access. The most consequential downstream effect of the equivalence finding is on clinic throughput. Because iTBS sessions require roughly one-third the chair time of 10 Hz rTMS, a clinic running iTBS can treat approximately three times as many patients in the same chair-hours. The expansion of access — the number of patients in Orange County who can actually be scheduled for a course — is materially larger under iTBS than it was under the original 10 Hz-only protocol.

Patient burden. Per-session in-chair time of 10–20 minutes (iTBS) versus approximately 40 minutes (10 Hz rTMS) is the difference between a TMS course that fits inside a lunch hour and a TMS course that does not. For patients balancing work, caregiving, or a long commute against five weekday sessions per week for six to nine weeks, the burden reduction is real.

Tolerability subtleties. Overall tolerability between the two protocols is comparable.¹ At the individual-patient level, however, some patients tolerate one protocol better than the other. The most commonly described pattern is that iTBS can be perceived as more intense per pulse — the patterned 50 Hz bursts deliver scalp sensation in a denser distribution — while 10 Hz rTMS produces a more gradual cumulative scalp and facial fatigue over its longer session. Patients who find one protocol intolerable can sometimes complete a course on the other; protocol switching for tolerability is a recognized clinical option.

Insurance coverage. Both protocols are FDA-cleared for the same indication and are covered under the same TMS payer policies; iTBS does not require a separate authorization track from 10 Hz rTMS. Most major commercial payers and Medicare cover TMS for major depressive disorder with prior authorization; the protocol choice is documented in the treatment plan but does not change the authorization framework.

What it does not mean

Equivalence is not superiority. The published data establish that iTBS matches 10 Hz rTMS on response and remission; they do not establish that iTBS is more effective. Marketing language that frames iTBS as a "next-generation" or "superior" protocol overstates the evidence.

Mid-course protocol switching for non-response remains debated. Whether a patient who is not showing measurable response by the mid-course assessment benefits from switching from one protocol to the other is an open question; current clinical consensus is to complete the started protocol unless tolerability mandates a change.² Evidence specifically supporting protocol-switching as a non-response strategy is limited.

The mechanism question is not fully settled. Both protocols engage LTP-like plasticity, but the precise reason an intensely patterned 3-minute iTBS train produces clinical effects comparable to a distributed 37-minute 10 Hz train remains an area of active research. Equivalence at the clinical level does not mean the two protocols are biologically identical at every level.

Key takeaways

• The headline finding — established in the THREE-D trial (Blumberger et al., Lancet 2018) and reinforced by Berlim 2017, Voineskos 2022, and Bulteau 2022 — is that iTBS produces equivalent response and remission rates to standard 10 Hz rTMS for major depressive disorder.
• Per-session in-chair time: approximately 10–20 minutes for iTBS vs approximately 40 minutes for 10 Hz rTMS, on a standardized 4–6 week, five-day-per-week course.
• Both protocols target the left DLPFC and engage the same LTP-like synaptic-plasticity mechanism; standard rTMS is delivered at 120% of motor threshold while our iTBS protocol is individualized and delivered at up to 90%, and the theta-burst pattern is more time-efficient, not more effective.
• The clinical implications of equivalence are about access and patient burden — clinics can treat roughly three times as many patients in the same chair-hours under iTBS — not about superior efficacy.
• Both protocols are FDA-cleared under the 510(k) pathway for adult major depressive disorder and are covered under the same TMS insurance authorization track; iTBS does not require separate prior authorization.
• Some patients tolerate one protocol better than the other; protocol switching for tolerability is a recognized clinical option, while mid-course switching for non-response is not supported by published evidence.

Patients across Anaheim and Orange County weighing whether the protocol choice changes their treatment options — and the patients with treatment-resistant depression for whom the in-chair time difference is the operational question that determines whether a course fits inside their week — typically find the answer clearer after a candidacy evaluation. Our team handles insurance verification directly before the first session, and the TMS therapy page documents the clinic's approach to protocol selection, candidacy, and the six-to-nine-week course described above.

Sources / Further reading